Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.70 |
| ▸ | RARB | P10826 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401721 | 0.98 | TP53 (0.69) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL177170 | 0.92 | PKM (0.69) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL2183388 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL7911508 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL26136333 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL2181009 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL209561 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL2180731 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| SCHEMBL14097198 | 0.92 | TP53 (0.82) | TP53TSHRPLA2G4BRARBHTT | |
| Hydrochloric Acid SCHEMBL2039843 | 0.91 | PKM (0.67) | TP53TSHRPLA2G4BRARBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| CN-101142180-B | Pyrrolidine derivatives as histamine h3 receptor antagonists | LILLY CO ELI | 2011-05-04 | — | — | CN | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| CN-101142180-A | Pyrrolidine derivatives as histamine h3 receptor antagonists | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | disclosed |
| US-5650416-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5631268-A | ANTIALLERGENS, 5HT2 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5602147-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5596003-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5541200-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5476861-A | Piperidinyl thiacyclic derivatives | MERRELL DOW PHARMACEURICALS INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0626968-A4 | — | — | 1995-01-04 | — | — | EP | disclosed |
| EP-0626968-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5371093-A | Piperidinyl thiacyclic derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-06 | — | — | US | disclosed |
| WO-1993016081-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | TP53 4281/4885TSHR 464/4885PLA2G4B 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.